Objective: One of the proteoglycan families is the small leucine-rich proteoglycans (SLRPs) that are characterized by their association with collagen fibrils and/or some glycosaminoglycans. Opticin is a glycoprotein and class III member of the SLRP family, which was initially identified in the vitreous humour of the eye. In this study, we first investigated whether opticin is expressed and produced in normal and OA human articular tissues/cells. Further, we investigated the ability of the key metalloprotease involved in cartilage pathology, MMP-13, to cleave human cartilage opticin.
Introduction
Osteoarthritis (OA) is the most prevalent form of rheumatologic disease, affecting more than 20 million people in the United States 1 . Worldwide estimates are that about 10% of men and 18% of women and about 60e65% aged over 60 years have symptomatic osteoarthritis, and 80% of those have limitations in movement. OA is characterized mainly by the degradation of articular cartilage with an imbalance between anabolic and catabolic pathways in which an increase in the proteolysis of aggrecan (proteoglycan) and collagen is prominent 2 . Proteoglycans form a large group that includes the small leucine-rich proteoglycans (SLRPs). The SLRP family, which is now thought to consist of 12 members 3 , is characterized by a protein core containing tandem leucine-rich repeats (LRRs) flanked by conserved cysteine residues 4 .
SLRPs also possess a variable amino-terminal extension to the LRR-containing region. Eleven of the 12 members of this family are divided into three classes based on their genomic organization, the number of LRR, and the consensus sequence of a cysteine cluster at the N-terminal end of the LRR domain 3e5 : class I includes decorin, biglycan and asporin; class II includes fibromodulin, lumican, keratocan, PRELP and osteoadherin; and class III includes epiphycan, mimecan and opticin. Their importance in extracellular matrix organization 5 was highlighted by the phenotype of some SLRP knock-out mice including decorin-null 6 , lumican-null 7 and fibromodulin-null 8 , which showed abnormal collagen fibrils with uneven diameter and irregular structure, suggesting that their presence is essential for normal fibril (and hence tissue) morphology.
Opticin (also known as oculoglycan; MIM*605127), a member of the third SLRP class, is an extracellular matrix glycoprotein that was first identified by Reardon et al. 9 and found associated with the collagen fibrils of the vitreous humour of the eye. Opticin mRNA has been detected in the non-pigmented ciliary epithelium of the eye 10e12 and a variety of non-ocular tissues including cartilage, brain, ligament, liver, testis, muscle and skin 9, 13, 14 . Opticin is a dimeric glycoprotein with each monomer being composed of eight LRRs 15 . While SLRPs are generally proteoglycans, opticin is an exception in that instead of possessing glycosaminoglycan side chain(s), it is a glycoprotein with an amino-terminal region containing a cluster of serine and threonine residues that are heavily substituted with sialylated O-linked oligosaccharides 9, 15 . Several SLRPs, including opticin, bind noncovalently to collagen fibrils and opticin may play a role in maintaining fibril spacing 16 . Recent studies have shown that opticin binds to glycosaminoglycans, including heparan sulfate and chondroitin sulfate 17 which are essential in cartilage structure and maintenance 18 , and that other putative functions include the inhibition of angiogenesis and growth hormone binding 19, 20 . Extracellular matrix turnover is an integral part of development, morphogenesis and tissue remodeling. While various types of proteases participate in matrix turnover, the matrix metalloproteases (MMPs) are the major matrix-degrading proteases in OA cartilage, and MMP-13 (collagenase-3) was found to be highly involved in this diseased tissue 21 . In addition to degrading type IeIII collagens, MMP-13 has a telopeptidase activity and the ability to degrade a number of other components of the extracellular matrix including fibronectin, fibrillin, types IV, IX, X and XIV collagens, gelatin, galectin-3, and aggrecan [see review, 22 ]. Recently, MMP-13 has demonstrated its ability to cleave some of the SLRPs, including biglycan, decorin, fibromodulin and lumican 23e26 . In the present study, we first investigated the production of opticin in human articular tissues/cells and then evaluated the effect of MMP-13 on opticin in human OA cartilage. Data showed, for the first time, that opticin is expressed and produced by human chondrocytes, synovial fibroblasts and subchondral bone osteoblasts. Moreover, MMP-13 is able to cleave opticin, which may result in its functional failure, thereby resulting in loss of matrix structure and function.
Materials and methods

SPECIMEN SELECTION
Normal human knee cartilage and synovial membranes were obtained within 12 h of death from individuals (mean age AE SD, 66 AE 5 years) who had no history of joint disease or metabolic bone disease and died of causes unrelated to arthritic diseases. The tissues were examined macroscopically and microscopically to ensure that only normal tissue was used. Individuals showing cartilage deterioration were not included in the normal group.
Human OA specimens were obtained from patients undergoing total knee arthroplasty (mean age AE SD, 71 AE 9). All patients were evaluated as having OA according to recognized American College of Rheumatology Clinical Criteria 27 . At the time of surgery the patients had symptomatic disease requiring medical treatment in the form of acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), or selective cyclooxygenase-2 inhibitors. None had received intra-articular steroid injections within 3 months prior to surgery, and none had received medication that would interfere with bone metabolism. The Institutional Research Ethics Committee of the University of Montreal Hospital Centre approved the use of the human articular tissues.
PROTEOGLYCAN EXTRACTION
Proteoglycans were extracted with guanidinium chloride, as previously described 26, 28 . Briefly, cartilage was finely diced and extracted with 4 mol/L guanidinium chloride (Invitrogen Inc., Carlsbad, CA, USA) in 0.1 mol/L sodium acetate (pH 6.0) containing protease inhibitors (leupeptin [10 mg/mL], pepstatin [10 mg/mL], aprotinin [10 mg/mL], 1,10-phenanthroline [10 mg/mL] and phenylmethanesulphonyl fluoride [100 mg/mL]) (EMD Biosciences Inc., La Jolla, CA, USA) at 4 C with continuous stirring for 48 h. The extract was then separated from the cartilage residue by filtration through glass wool, and then dialysed for 48 h against 50 mmol/L Tris buffer (pH 7.5).
OPTICIN mRNA DETECTION
Chondrocytes and synovial fibroblasts were released from full-thickness strips of articular cartilage and synovial membrane, respectively, by sequential enzymatic digestion at 37 C, as previously described 29 . The cells were seeded at high density (10 5 cells/cm 2 ) in tissue culture flasks and cultured in Dulbecco's modified Eagle's medium (DMEM; GibcoeBRL, Burlington, ON, Canada) supplemented with 10% heat-inactivated fetal calf serum (FCS; GibcoeBRL) and an antibiotic mixture (100 units/mL penicillin base and 100 mg/mL streptomycin base; GibcoeBRL) at 37 C in a humidified atmosphere of 5% CO 2 /95% air. Cells were maintained in culture for 5e7 days. Primary cell cultures were used. Subchondral bone osteoblast release was as previously described 30 . In brief, the overlying cartilage was removed and the trabecular bone tissue dissected from the subchondral bone plate. All manipulations were performed under a magnifying microscope to ensure the complete removal of cartilage and trabecular bone. Bone samples were cut into small pieces prior to sequential digestion in the presence of collagenase type I in BGJb medium without serum at 37 C in a humidified atmosphere. After a 4-h incubation period the bone pieces were cultured in BGJb medium containing 20% FCS and the antibiotic mixture at 37 C. This medium was replaced every 2 days until cells were observed in the petri dishes. At this point, the culture medium was replaced with fresh medium containing 10% FCS until confluence. Osteoblasts passaged once were used.
Total cellular RNA from cells was extracted with the TRIzolÔ reagent (Invitrogen) according to the manufacturer's specifications and treated with the DNA-freeÔ DNase Treatment and Removal kit (Ambion, Austin, TX, USA) to ensure the complete removal of chromosomal DNA. The RT reactions were primed with random hexamers as described previously 31 , with 2 mg of total RNA in a 20 ml final reaction volume. The polymerase chain reaction (PCR) was carried out for 40 cycles of 94 C for 1 min and an annealing/extension step at 60 C for 1 min and 30 s. Primers were derived from the published sequence of the opticin gene (access #NM014359). The primers 5 0 -TTGACCTCTCCAACAACCTC-3 0 (forward) and 5 0 -GGTCACAGAAGACG TCTCTC-3 0 (reverse) amplified a single 327 bp fragment. The identity of the amplified fragment was tested by (1) restriction with Pst1, which specifically cleaves the fragment, and (2) by DNA sequencing.
OPTICIN CLEAVAGES BY MMP-13
MMP-13 proteolytic activity was analyzed on proteoglycan extracts from normal and OA human cartilage having different levels of fibrillation corresponding to different stages of the disease process. These were named slightly, moderately and severely fibrillated cartilage. These extracts were incubated for 0e16 h with human recombinant (rh)MMP-13 (R&D Systems Inc., Minneapolis, MN, USA) activated with 0.5 mmol/L aminophenylmercuric acetate (APMA; Kodak Inc., Toronto, ON, Canada) in 50 mmol/L TriseHCl (pH 7.5) containing 10 mmol/L CaCl 2 and 0.05% Brij 35 (SigmaeAldrich Canada Ltd., Oakville, ON, Canada) at an MMP-13/proteoglycan ratio of 1:50 (100 ng/5 mg). Glycosaminoglycan content was determined by the DMMB method 32 . The reaction was stopped by the addition of EDTA (SigmaeAldrich Canada Ltd.) at a final concentration of 15 mM. WESTERN BLOTTING MMP-13 treated and non-treated proteoglycan extracts were mixed with a sample buffer (62.5 mmol/L TriseHCl [pH 6.8], 2% w/v sodium dodecyl sulphate, 10% glycerol, 5% b-mercaptoethanol and 0.05% bromophenol blue) and electrophoresed on 4e20% Ready-Gels (Bio-Rad Laboratories Ltd., Mississauga, ON, Canada). The proteoglycan extracts were then transferred electrophoretically onto nitrocellulose membranes (Bio-Rad Laboratories Ltd.) and processed for Western immunoblotting. Blots were blocked in 5% low fat dry milk in Tris-buffered saline containing 0.05% Tween 20 (SigmaeAldrich Canada Ltd.). The primary antibody was a polyclonal rabbit that recognizes the N-terminus of the human opticin core protein as described previously 11 . For Western blotting a 1/10,000 dilution was used. The secondary antibody was a horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (1/10,000 dilution; Pierce, Rockford, IL, USA). For comparison purposes, another antibody was also used: a polyclonal goat anti-human opticin (#AF3148; R&D Systems, Minneapolis, MN, USA) at a 1/2000 dilution. The secondary antibody was a mouse anti-goat immunoglobulin (1/10,000 dilution; Pierce). Detection was performed by chemiluminescence using the Super Signal Ò West Dura Extended Duration substrate (Pierce), in accordance with the manufacturer's specifications.
IMMUNOHISTOCHEMISTRY
Cartilage and synovial membrane specimens were processed for immunohistochemistry as previously described 33 . The specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Sections (5 mm) of paraffin-embedded specimens were deparaffinized in toluene and rehydrated in a graded series of ethanol. The cartilage specimens were then pre-incubated with chondroitinase ABC (0.25 units/mL in PBS [pH 8.0]) for 60 min at 37 C, and both cartilage and synovial membrane with Triton X-100 (0.3%) for 30 min at room temperature. Slides were then washed in PBS followed by 0.3% hydrogen peroxide/methanol for 30 min. They were further incubated for 60 min with 2% normal serum (Vector Laboratories, Burlingame, CA, USA) and overlaid with the rabbit anti-human opticin antibody (1/1000 dilution) for 18 h at 4 C in a humidified chamber. The second antibody was a goat anti-rabbit immunoglobulin (Vector Laboratories).
Each slide was washed three times in PBS (pH 7.4) and stained using the avidinebiotin complex method (Vectastain ABC kit; Vector Laboratories). The color was developed with 3,3 0 -diaminobenzidine (Vector Laboratories) containing hydrogen peroxide. The slides were counter-stained with eosin. Controls were done to determine the specificity of staining: (1) substitution of the primary antibodies with non-specific rabbit IgG (Chemicon International, Temecula, CA, USA) used at the same concentration as the primary antibody; (2) immunoadsorbed with 25-fold excess of the recombinant opticin; and (3) omission of primary antibody. Controls showed only background staining.
The total number of chondrocytes and the total number of positively stained chondrocytes were counted as previously described 33 . As no chondrocytes staining positive were found in the deep zone (lower intermediate and deep layers), the final results were expressed as the percentage of positive chondrocytes of the superficial zone (superficial and upper intermediate layers). Briefly, for each cartilage specimen, the total number of chondrocytes and the total number of positive chondrocytes were counted separately, at 40Â magnification, from three fields of the superficial zone. Each slide was subjected to a double-blind evaluation with a variation of <5%.
PROTEIN SEQUENCING OF MMP-13 OPTICIN CLEAVAGE PRODUCT
Bovine recombinant opticin 15 was incubated with APMA-activated rhMMP-13 in 50 mmol/L TriseHCl (pH 7.5), containing 10 nmol/L CaCl 2 and 0.05% Brij 35, for 8 h at 37 C. The reaction was stopped by the addition of EDTA at a final concentration of 15 mM. Degradation products were separated in 4e20% polyacrylamide gels (Bio-Rad Laboratories Ltd.). After electrophoresis, the gels were soaked in CAPS transfer buffer (10 nmol/L 3-cyclohexylamino-1-propanesulfonic acid, 10% methanol [pH 11.0]) for 15 min at 0.25 A. After washing, the protein was transferred onto PVDF membranes (Millipore Corporation, Bedford, MA, USA), which were washed in deionized water, stained with 0.1% Coomassie Blue in 50% methanol for 5 min, and then destained in 50% methanol and 10% acetic acid for 5e7 min at room temperature. Finally, the membrane was rinsed in deionized water, air dried and stored at room temperature. Amino-terminal amino acid sequencing of the protein band was performed on a Procise Protein Sequencer model 492 (Applied Biosystems, Foster City, CA, USA).
Results
OPTICIN EXPRESSION BY HUMAN OA ARTICULAR CELLS
As represented in Fig. 1 , opticin is expressed in human OA chondrocytes (n ¼ 3), synovial fibroblasts (n ¼ 3) and subchondral bone osteoblasts (n ¼ 3). In order to confirm the specificity of the band, they were treated with the enzyme Pst1, and data indicate that the enzyme specifically cleaves the fragment (Fig. 1) . Further DNA sequencing confirmed that the amplificated fragment of the reverse transcriptase-PCR (RT-PCR) corresponded to human opticin.
Further data showed that opticin is produced in both normal (n ¼ 2) and OA (n ¼ 4) human synovial membranes and cartilages (normal, n ¼ 6; OA, n ¼ 6) [ Fig. 2(A and B) ]. In both normal and OA synovial membranes, opticin is produced in the synovial lining cells and in the endothelial cells of the vessel wall, as well as in cell infiltration in OA [ Fig. 2(A) ]. Of note, although opticin is found in the same cells when OA and normal tissues are compared, there are, in the OA synovial membrane, more layers of the lining cells as well as cell infiltration, thus more cells producing opticin.
In cartilage [ Fig. 2(B) ], chondrocytes producing opticin are found mostly in the superficial layers of the tissue for both cartilage types. Analysis of opticin positive chondrocytes at this level showed that although a higher level of positive chondrocytes was found in OA samples, this did not reach statistical significance [ Fig. 2(C) ]. Interestingly, matrix opticin specific staining was present in normal cartilage, but had almost disappeared in OA cartilage [ Fig. 2(B) ]. The disappearance of the matrix staining occurred in all OA specimens regardless of the severity of the disease (data not shown).
MMP-13-INDUCED OPTICIN DEGRADATION
Western blotting revealed that the cartilage extracted human opticin differed in the apparent molecular weight from the bovine recombinant opticin. As illustrated in Fig. 3(A) ], data showed that bovine opticin migrated at an apparent molecular weight of 40e45 kDa whereas the human opticin migrates as a doublet of 55e60 kDa. To verify that the immunoreactivity was not due to the rabbit antihuman antibody, another antibody, a goat anti-human, was used and results were similar [ Fig. 3(A) ]. In any case, none of the antibodies used recognized a 40e45 kDa fragment.
Specimens incubated with MMP-13 showed that opticin degradation was time-dependent and clearly visible after 2 h of incubation, and almost complete at 8 h [ Fig. 3(B) ]. No true differences in the opticin degradation were observed between the specimens from normal and OA cartilages according to the degree of cartilage fibrillation severity.
MMP-13 CLEAVAGE SITE OF OPTICIN
Amino-terminal amino acid sequencing was performed on the major opticin fragment of approximately 24 kDa produced by MMP-13 digestion (Fig. 4) . Two sequences were identified which corresponded to a major cleavage between positions G 104 and L 105 LAAP, and a minor one between positions P 109 and A 110 NHPG of the mature opticin core protein. Therefore the 24-kDa fragment was composed of the LRR domains with flanking cysteines, but the amino-terminal domain containing the sialylated O-linked oligosaccharides has been removed by MMP-13 digestion.
Discussion
The present study showed for the first time that opticin is expressed in human knee tissues including articular cartilage, synovial membrane and subchondral bone and the protein has been identified in cartilage and synovial membrane. Interestingly, MMP-13 cleavage of opticin in cartilage occurred early and was extensive, suggesting that this molecule is a preferential substrate among the SLRPs for this enzyme. We also characterized the major cleavage site for opticin and this was located between amino acids G 104 and L 105 . We hypothesize that MMP-13-induced opticin degradation may represent an early critical event in the process of cartilage degradation.
Opticin exists as a noncovalently linked dimer in solution but runs as a monomer on SDS-PAGE. Recombinant bovine opticin ran as a diffuse component at approximately 45 kDa. The opticin in the human cartilage extract migrated somewhat more slowly (approximately 55e60 kDa by SDS-PAGE). It is assumed that the differences in electrophoretic migration are due to differences in the extent of O-glycosylation. Opticin is the only SRLP known to contain a large cluster of sialylated O-linked oligosaccharides, thereby providing an alternative form of anionic carbohydrate to the more usual glycosaminoglycan chains 5, 9 . The functional significance of the sialylated O-linked oligosaccharides on opticin remains unknown. OA is a multifactorial disorder involving cartilage, synovial membrane and subchondral bone 34 , and in each of these tissues MMP-13 has been found in increased amounts and appears responsible, at least in part, for the tissue degradation. Although MMP-13 acts on various matrix macromolecules, this is the first time that its effect was investigated on a member of the class III SLRPs. Here, we assessed the degradative effect of MMP-13 on opticin on normal human cartilage and on three different stages of OA cartilage. Data showed that MMP-13 cleaves opticin, and that the degree of degradation was independent of the cartilage damage severity. MMP-13 has different catalytic activities including collagenolytic and gelatinolytic, in addition to showing strong aggrecanase properties 35, 36 . Therefore, depending on the substrate, it can degrade SLRPs with its collagenase or gelatinase activity, or with both, resulting in a faster degradation of the substrate 26 . Our data suggest that opticin is sensitive to both of the MMP-13 catalytic activities, since, in comparison with the degradation speed for biglycan and fibromodulin 26 , the degradation of the glycoprotein occurs early and is clearly visible after only 2 h of incubation.
The 24-kDa band obtained in the opticin digestion with MMP-13 included two fragments: a major one that has been cleaved between positions G 104 and L 105 LAAP, and the minor one between positions P 109 and A 110 NHPG. Efforts have been devoted to establish the consensus cleavage motif of each MMP. However, a specific pattern could not be ascertained as the MMP cleavage sites for the different substrates share little sequence homology and lack an obvious consensus cleavage motif. Here, the fact that MMP-13 cleaves opticin at two different but close sites without any homology may indicate that the recognition and cleavage sites are distinct. One possibility is that MMP-13 first binds to a region and then cleaves opticin some amino acids away from this recognition site. A second hypothesis is that, if collagenolytic and gelatinolytic MMP-13 activities are working together, each of them could recognize different cleavage sites on opticin. Another point of interest is that a fragment of a similar size is also noted in the control (untreated recombinant opticin), indicating the occurrence of such a cleavage in the cell from which the opticin was purified, hence this MMP-13 activity could have occurred in vivo. This could very well be the case, as the recombinant opticin was purified from human embryonic kidney cells 13 , and MMP-13 is active during embryonic development 37, 38 . It is then possible that the MMP-13 opticin fragment was also purified along with the mature opticin, although we cannot exclude the possibility that other proteases exerted this effect. However, the fact that it could be seen in an increased intensity of the band after the treatment with the protease suggests that MMP-13 is related to this digestion.
Of note, is that the 24-kDa fragment could not be detected with the antibodies used in this study. This could be explained by the fact that the antibodies recognized the N-terminus of the core protein, and that the fragment is at the C-terminus region of the opticin.
As MMP-13 has been suggested to be present in cartilage during its remodelling 39, 40 , hence at an early stage of the disease, it is tempting to hypothesize that opticin cleavage may represent an early critical event. Opticin may have a direct involvement in maintaining the spacing of collagen fibrils and therefore degradation of opticin could cause direct structural damage. Alternatively, the degradation of opticin may affect the collagen network by uncovering the collagenase cleavage site on this molecule or it could expose proteoglycans to cleavage since it has been shown to bind chondroitin sulphate and heparin sulphate 17 . The degradation of collagen and/or proteoglycans would lead to cartilage degeneration. This hypothesis is supported by our data showing the ability of MMP-13 to cleave opticin in a similar manner in normal and OA cartilages. Moreover, the finding that opticin in normal cartilage, in contrast to OA, had a high level of matrix staining in the superficial zone indicates that in situ in OA cartilage, opticin in the matrix is degraded and that the degradation product may not be retained within the cartilage matrix, hence it does not accumulate. The degradation of opticin by MMP-13 in situ in OA cartilage is further supported by the fact that this enzyme is produced at a very low level in normal cartilage 29, 41, 42 , and that in OA, this protease is detected in all cartilage layers 39, 40 . In addition, the lack of difference in chondrocytes producing opticin between normal and OA cartilage indicates that the production of this SLRP is not modulated in this tissue by the events occurring during the disease process, emphasizing the importance of the degradation of this molecule during the pathological progression. This could also apply to the synovial membrane, where there was no difference in the cell types producing opticin in normal and OA.
In this study, we examined the effect of MMP-13 on opticin, as this MMP is highly involved in OA pathogenesis. However, this does not rule out that this SLRP could be degraded by other proteases also involved in this disease process. In this context, it has recently been shown 43 that a member of the SLRP family, the biglycan, can be cleaved by the aggrecanases, but not decorin which belongs to the same SLRP class. More should be known about the consensus sequence recognition of each protease in order to predict which proteases could interact with each of the SLRP members.
In summary, opticin is present in human articular tissues and MMP-13 has the ability to cleave it. The fact that MMP-13 could cleave numerous cartilage matrix components, including type II collagen and members of the SLRPs, that bind to this collagen, could explain why this collagenase plays a major role in osteoarthritis.
